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Prostatic ductal adenocarcinoma (PDA) is a rare and aggressive
subtype of prostate cancer that has a worse prognosis than the
more common prostatic acinar adenocarcinoma (PAA). Treatment
of PDA has yet to be standardized. We present a case of PDA where
despite clear surgical margins therewas local recurrence of disease.
2. Case presentation
An 80 year old male was diagnosed with incidental PDA on a
transurethral resection of prostate specimen (pT1b). Approxi-
mately 15% of the prostate tissue examined contained multiple foci
of PDA mixed with PAA. His preoperative digital rectal assessment
had been non-suspicious with a serum prostate-speciﬁc antigen
(PSA) of 8.9 mg/L. Conventional imaging includingwhole-body bone
scan and staging computed tomography scanwere not indicative of
metastatic disease. Based on institutional standards, the patient
underwent cystoprostatectomy, pelvic lymph node dissection,
partial urethrectomy and urinary diversion with an ileal-conduit.
The distal third of the penile urethra was spared.
Histopathological assessment of the resected specimen
demonstrated malignant involvement of both sides of the prostate
with approximately 70% of the gland involved. The PAA component* Corresponding author. Department of Urology, Royal Melbourne Hospital, 300
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nent was graded as Gleason 4 þ 5 ¼ 9 (ISUP V) and contained
scattered foci of comedo necrosis representing high grade tumour.
There was extraprostatic invasion into the bladder neck wall, left
seminal vesicle and perivesical fat. A 1.5 mm focus of PDA was
present in the proximal urethral tissue with a clear surgical margin.
Six months postoperatively the patient developed bloody penile
discharge. On urethroscopy a large papillary tumour was noted
(Fig. 1 A). Biopsy of the tumour indicated a malignant process
focally positive for PSA suggesting a recurrence of PDA. The patient
underwent a radical penectomy where a 7 mm pure ductal
adenocarcinoma with penile stromal invasion was identiﬁed (Fig. 1
B, C, D). Three months postoperatively there were no clinical signs
of recurrence and the serum PSA was undetectable.3. Discussion
PDA has held a controversial spot in the prostate cancer scien-
tiﬁc literature since ﬁrst being identiﬁed in 1967 by Mellicow.1
There have been conﬂicting reports about its prognosis, aggres-
siveness and even its existence as a separate clinical entity.2
However recent studies suggest that PDA is prostate cancer sub-
type that has a worse prognosis when compared to the more
common PAA.3 Its characterization has been limited by its low
prevalence, approximately 0.4e0.8% in its pure form and up to 5%
mixed with PAA.3
Histologically PDA tends to be made up of tall pseudostratiﬁed
columnar epithelium organised into either papillary or cribriform
patterns.4 It tends to occur in the transitional zone and is associated
with urethral invasion. Therefore many patients, even with
advanced PDA, may have normal digital rectal examinations. Clin-
ical detection is made even more difﬁcult as PDA has a tendency to
present with reduced serum PSA levels when compared to PAA.3
These factors often lead to late identiﬁcation and advanced dis-
ease at diagnosis.
There are currently no standardized recommended treatment
guidelines of PDA and its management is based on established
therapeutic options for PAA and a small number of PDA case series/
studies.4 Localised PDA is typically treated with radicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A Papillary lesion macroscopically visible on urethroscopy. B Histopathology of penectomy specimen at 2magniﬁcationwith the urethra passing from the right of the image
into the malignancy. C Histopathology of penectomy specimen at 10 magniﬁcation. D Histopathology of penectomy specimen at 40 magniﬁcation.
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depending on disease extension. Androgen deprivation therapy has
been reported as being non-effective to partially effective.
Chemotherapy, particularly cycles of docetaxel, has been trialled in
patients with metastatic PDA with varying success. The effect of
radiotherapy has been reported in small case series and has shown
good local control in the treatment of PDA.5
Our institutional preference for the treatment of localized PDA is
cystoprostatectomy and urethrectomy. In this scenario total ure-
threctomy was not performed and despite clear surgical margins
the patient developed local recurrence in the distal urethra. Our
case report lends to the developing body of research that PDA is an
aggressive subtype of prostate cancer. This case highlights that a
total urethrectomy and adjuvant therapies should be considered in
order to minimize the risk of local recurrence despite clear surgical
margins.
Due to the lack of robust data in PDA there is need for future
research in this ﬁeld in order to make considerations for optimal
primary as well as adjuvant treatment for this rare subtype of
prostate cancer.
4. Conclusion
PDA is an aggressive subtype of prostate cancer that requiresfurther research in order to develop standardized treatment
guidelines. Complete urethrectomy and appropriate adjuvant
therapies should be considered in localized disease to reduce the
risk of urethral recurrence.Acknowledgments
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